Lung Cancer – High-Yield Study Guide for Medical Students
Definition
Lung cancer is a malignant epithelial tumor arising from the lower respiratory tract, usually from bronchial or alveolar epithelium, and is broadly classified into non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma; it accounts for ~80–85% of cases, while SCLC accounts for ~15–20% and is characterized by rapid growth and early dissemination.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
Epidemiology
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with a high burden of disease despite improvements in screening and therapy.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
- Incidence: Among the most commonly diagnosed cancers globally; adenocarcinoma is now the most frequent histologic subtype, particularly in never-smokers and women.
- Mortality: Leading cause of cancer death in both men and women due to late presentation and high metastatic potential.
- Age: Typically presents in the 6th–7th decade; rare below age 40.
- Sex: Historically more common in men, but the gap has narrowed due to changing smoking patterns and increased adenocarcinoma in women.
- Geography: Higher incidence in regions with high smoking prevalence and environmental/occupational exposure (e.g., radon, air pollution).
Major Risk Factors
- Cigarette smoking: Most important risk factor; risk correlates with pack-years and is higher with early age of initiation and deep inhalation.
- Secondhand smoke and environmental tobacco exposure.
- Occupational exposures: Asbestos, arsenic, chromium, nickel, silica, diesel exhaust.
- Radon gas: Second leading cause of lung cancer in many areas; synergistic with smoking.
- Air pollution: Fine particulate matter and indoor biomass fuels increase risk.
- Prior chest radiation: Especially in survivors of lymphoma, breast cancer, or childhood malignancies.
- Genetic factors: Family history, germline variants, and somatic driver mutations (e.g., EGFR, ALK, KRAS, ROS1) influence susceptibility and tumor biology.[10](https://europepmc.org/article/MED/41289566)
- Chronic lung disease: COPD, pulmonary fibrosis, and prior TB scars increase risk.
Pathophysiology
Lung carcinogenesis is driven by accumulation of genetic and epigenetic alterations in bronchial or alveolar epithelial cells, often triggered by carcinogens (especially tobacco smoke) and modulated by host and microenvironmental factors. These changes lead to dysregulated proliferation, inhibition of apoptosis, genomic instability, angiogenesis, immune evasion, and metastatic capacity.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
Key Molecular and Cellular Mechanisms
- Genetic mutations: Activating mutations in oncogenes (e.g., EGFR, ALK rearrangements, ROS1, BRAF, MET, RET, KRAS) and loss of tumor suppressor genes (e.g., TP53, RB1) drive uncontrolled cell growth and survival. Emerging data identify additional regulators such as PKMYT1 as potential oncogenic drivers and prognostic biomarkers in lung adenocarcinoma.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
- Disordered cell death and autophagy: Proteins such as NIX/BNIP3L participate in mitophagy and cell death pathways and can act either as tumor suppressors or tumor promoters depending on the context, contributing to metabolic adaptation and survival of cancer cells.[2](https://pubmed.ncbi.nlm.nih.gov/41744611/)
- Tumor microenvironment (TME): Interactions between cancer cells, immune cells, fibroblasts, and extracellular matrix shape tumor behavior. Deep-learning analyses of histopathology have shown that TME features strongly correlate with specific driver mutations (e.g., EGFR, ALK, KRAS, others).[10](https://europepmc.org/article/MED/41289566)
- MicroRNAs and non-coding RNAs: miRNAs (e.g., miR-127-3p) and long noncoding RNAs modulate signaling pathways controlling migration, invasion, and resistance to therapy; in lung adenocarcinoma, miR-127-3p suppresses cell migration under both normoxic and hypoxic conditions.[6](https://europepmc.org/article/MED/39483961)
- JAK/STAT signaling: Dysregulated JAK2/STAT3 signaling promotes proliferation, survival, and immune evasion. Preclinical work shows that targeting this pathway (e.g., combining isoliquiritigenin with gemcitabine via lncRNA-p21/miR-4534 modulation) can inhibit lung cancer growth, highlighting the centrality of these signaling cascades.[8](https://europepmc.org/article/MED/41735617)
Histologic and Molecular Subtypes
- Adenocarcinoma (NSCLC): Arises from peripheral lung parenchyma; associated with gland-forming or mucin-producing cells. Common in never-smokers and women; frequently harbors EGFR mutations, ALK/ROS1 rearrangements, and other targetable alterations.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
- Squamous cell carcinoma (NSCLC): Centrally located, strongly associated with smoking; often presents with cavitation and local bronchial obstruction.
- Large cell carcinoma (NSCLC): Poorly differentiated tumors lacking features of adenocarcinoma or squamous cell carcinoma; diagnosis of exclusion.
- Small cell lung cancer (SCLC): Highly aggressive neuroendocrine tumor with early metastasis, frequent paraneoplastic syndromes, and strong association with smoking.
Clinical Presentation
Presentation varies from asymptomatic early disease (often detected on screening CT) to advanced disease with local, regional, and distant manifestations. Many patients present late with symptoms driven by tumor size, location, or metastases.
Local and Intrapulmonary Symptoms
- Cough: New-onset or change in chronic cough, especially in smokers.
- Hemoptysis: Blood-streaked sputum to frank hemoptysis, especially with central lesions.
- Dyspnea: Due to airway obstruction, collapse, pleural effusion, or underlying COPD.
- Pleuritic chest pain: With pleural invasion or peripheral lesions.
- Recurrent or non-resolving pneumonia: Particularly in the same lobe, suggesting an obstructing endobronchial mass.
- Wheezing/stridor: Central airway narrowing.
Regional (Thoracic) Spread
- Hoarseness: Recurrent laryngeal nerve involvement.
- Superior vena cava (SVC) syndrome: Facial and upper extremity swelling, venous distention due to SVC obstruction, classically with SCLC or bulky mediastinal disease.
- Horner syndrome: Ptosis, miosis, anhidrosis from sympathetic chain involvement (Pancoast tumor at lung apex).
- Dysphagia: Esophageal compression.
- Pericardial effusion or tamponade: From direct invasion or metastases.
Distant Metastatic Disease
- Brain: Headache, seizures, focal neurologic deficits, cognitive changes.
- Bone: Bone pain, pathologic fractures, spinal cord compression.
- Liver: RUQ discomfort, hepatomegaly, abnormal LFTs.
- Adrenal glands: Usually asymptomatic; occasionally adrenal insufficiency.
- Systemic: Weight loss, anorexia, fatigue, cachexia.
Paraneoplastic Syndromes
- SCLC: SIADH (hyponatremia), ectopic ACTH (Cushing syndrome), Lambert–Eaton myasthenic syndrome, paraneoplastic encephalomyelitis.
- Squamous cell carcinoma: PTHrP-mediated hypercalcemia.
- Hypertrophic osteoarthropathy: Clubbing and periostitis of long bones.
- Dermatologic, hematologic, or neurologic manifestations: Various autoimmune and paraneoplastic phenomena.
Diagnosis
Diagnosis requires integration of clinical assessment, imaging, histopathology, and molecular profiling. Staging is essential for prognostication and treatment planning.
Initial Evaluation
- History and physical examination: Assess risk factors (smoking, occupational exposures, prior malignancy or radiation), symptom duration, and performance status.
- Chest imaging:
- Chest X-ray: Often first test, may show mass, consolidation, atelectasis, or pleural effusion.
- CT chest with contrast: Defines location, size, mediastinal invasion, lymphadenopathy, and guides biopsy.
- Low-dose CT screening: In high-risk populations (e.g., heavy smokers) detects early-stage disease and improves survival.
Histologic Diagnosis
- Bronchoscopy with biopsy: Best for central lesions and endobronchial tumors; allows biopsy, brushings, washings, and EBUS-guided nodal sampling.
- CT-guided percutaneous needle biopsy: Preferred for peripheral masses.
- Thoracentesis and pleural fluid cytology: For malignant pleural effusions.
- Video-assisted thoracoscopic surgery (VATS) or open biopsy: When less invasive methods are nondiagnostic.
Staging
- NSCLC: Staged by the TNM system (tumor size/extent, nodal involvement, metastases). Staging guides selection of surgery, radiation, and systemic therapy.
- SCLC: Traditionally classified into limited stage (confined to one hemithorax and regional nodes within a single radiation field) and extensive stage (beyond that), though TNM staging is also used.
- Imaging for staging:
- Contrast-enhanced CT of chest and upper abdomen.
- PET-CT: Detects nodal and distant metastases; improves staging accuracy and reduces unnecessary thoracotomies.
- Brain MRI: Recommended in most stage III–IV NSCLC and all SCLC patients due to high risk of CNS metastases.
Molecular Profiling and Biomarkers
- Driver mutations: Routine testing for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, and others is standard in advanced NSCLC to identify targeted therapy options. Deep learning models using histology can predict some driver mutations based on tumor and microenvironmental features, supporting precision oncology approaches.[10](https://europepmc.org/article/MED/41289566)
- PD-L1 expression: Assessed by immunohistochemistry to guide immune checkpoint inhibitor use.
- Emerging biomarkers: Kinases such as PKMYT1 may have prognostic and immunologic significance in lung adenocarcinoma and could inform future therapeutic strategies.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
Management
Management is stage-specific and histology-specific, and increasingly biomarker-driven. Therapeutic strategies include surgery, radiotherapy, systemic therapy (chemotherapy, targeted therapy, immunotherapy), and supportive/palliative care.
Management of Non–Small Cell Lung Cancer (NSCLC)
Early-Stage (Stage I–II, Selected IIIA)
- Surgery:
- Lobectomy with systematic lymph node dissection is standard for operable early-stage NSCLC in patients with adequate pulmonary reserve.
- Segmentectomy or wedge resection may be considered for small peripheral tumors or patients with limited pulmonary function.
- Adjuvant therapy:
- Platinum-based chemotherapy for selected stage II–IIIA disease to improve survival.
- Adjuvant targeted therapy (e.g., EGFR inhibitors) or immunotherapy is used in biomarker-selected high-risk patients in contemporary practice.
- Definitive radiotherapy: For medically inoperable patients, stereotactic body radiotherapy (SBRT) offers high local control comparable to surgery in selected early-stage tumors.
Locally Advanced (Stage III)
- Multimodality therapy: Treatment frequently involves combined chemotherapy, radiotherapy, and sometimes surgery depending on resectability and nodal involvement.
- Concomitant chemoradiation: Standard for unresectable stage III disease, followed by consolidation immunotherapy in many cases.
- Radiotherapy optimization: Techniques such as deep inspiration breath-hold (DIBH) can reduce dose to heart, esophagus, and spinal cord while maintaining tumor coverage, improving dosimetric outcomes in stage III NSCLC radiotherapy.[4](https://pubmed.ncbi.nlm.nih.gov/41687662/)
Metastatic or Recurrent (Stage IV)
- Systemic therapy is the mainstay: Choice depends on histology, molecular profile, PD-L1 status, burden of disease, and performance status.
- Targeted therapy:
- EGFR tyrosine kinase inhibitors (e.g., osimertinib) for EGFR-mutant NSCLC.
- ALK inhibitors (e.g., alectinib, brigatinib, lorlatinib) for ALK-positive NSCLC. Real-world data show lorlatinib is effective and safe as both first-line and subsequent-line treatment in ALK-positive NSCLC, achieving meaningful responses and PFS in Chinese cohorts.[5](https://pubmed.ncbi.nlm.nih.gov/41659264/)
- Other targeted agents for ROS1, BRAF V600E, MET exon 14 skipping, RET fusions, NTRK fusions, and KRAS G12C mutations.
- Immunotherapy:
- Immune checkpoint inhibitors (PD-1/PD-L1 inhibitors, with or without CTLA-4 inhibitors) are widely used in advanced NSCLC.
- Monotherapy or in combination with chemotherapy based on PD-L1 expression and tumor burden.
- Cytotoxic chemotherapy: Platinum-based doublets (e.g., carboplatin–pemetrexed for non-squamous, carboplatin–paclitaxel for squamous) remain important, especially when no driver mutation or immunotherapy contraindications exist.
- Local therapy for oligometastatic disease: SBRT or surgery for isolated metastases (e.g., brain, adrenal) can be considered with systemic therapy.
Management of Small Cell Lung Cancer (SCLC)
- Limited-stage SCLC:
- Concurrent chemoradiotherapy (platinum–etoposide with thoracic radiation) is standard.
- Prophylactic cranial irradiation (PCI) is often given in responders due to high risk of brain metastases.
- Extensive-stage SCLC:
- Systemic chemotherapy (platinum–etoposide) combined with immunotherapy (e.g., PD-L1 inhibitors) is commonly used.
- Palliative thoracic radiotherapy and local management of metastases as needed.
Management of Bone Metastases and Skeletal-Related Events
- Bone metastases are common in advanced lung cancer and can cause pain, fractures, spinal cord compression, and hypercalcemia.
- Antiresorptive therapy: Agents such as denosumab or bisphosphonates are used to prevent skeletal-related events (SREs) and improve quality of life. Real-world studies in lung cancer with bone metastases have evaluated denosumab’s association with 2-year all-cause mortality and incidence of SREs, highlighting its role in supportive care.[3](https://pubmed.ncbi.nlm.nih.gov/41707577/)
- Palliative radiotherapy: Targeted to painful bone lesions or areas at high risk of fracture.
Radiation-Induced Lung Injury
- Thoracic radiotherapy can cause radiation pneumonitis and later radiation fibrosis. Multi-omics studies reveal complex temporal changes in lung tissue involving transcriptomic, proteomic, and metabolic reprogramming that underlie these injuries, emphasizing the need for careful planning and dose constraints.[9](https://europepmc.org/article/MED/41814364)
- Clinical vigilance for cough, dyspnea, and new infiltrates after radiotherapy is crucial for early detection and management.
Emerging and Experimental Strategies
- Biomarker-driven therapies: Targeting novel kinases (e.g., PKMYT1) or death/autophagy regulators (e.g., NIX/BNIP3L) may offer future therapeutic options, especially in resistant disease.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/), [2](https://pubmed.ncbi.nlm.nih.gov/41744611/)
- Modulation of non-coding RNAs: Preclinical data show that manipulating miRNAs and lncRNAs (e.g., miR-127-3p, lncRNA-p21) can inhibit migration and sensitize tumors to chemotherapy through JAK2/STAT3 pathway modulation.[6](https://europepmc.org/article/MED/39483961), [8](https://europepmc.org/article/MED/41735617)
- AI and deep learning: Deep learning frameworks leveraging tumor and microenvironmental features on pathology slides can accurately predict multiple driver gene mutations, supporting personalized treatment planning.[10](https://europepmc.org/article/MED/41289566)
Key Clinical Pearls for Medical Students
- Think lung cancer in any smoker with a new or changing cough, hemoptysis, or recurrent pneumonia, especially localized to the same lobe.
- Adenocarcinoma is now the most common histologic subtype, including in never-smokers and women, and is frequently associated with targetable mutations.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/)
- Always consider paraneoplastic syndromes (SIADH, ectopic ACTH, Lambert–Eaton, PTHrP hypercalcemia) in unexplained electrolyte or neurologic abnormalities, especially in heavy smokers.
- Staging dictates treatment: Early-stage NSCLC is primarily surgical; locally advanced disease requires multimodality therapy; metastatic disease is managed with systemic therapy tailored by biomarkers.
- Molecular profiling is central to modern lung cancer care: Identifying driver mutations and PD-L1 expression is essential for appropriate targeted and immunotherapy selection.[5](https://pubmed.ncbi.nlm.nih.gov/41659264/), [10](https://europepmc.org/article/MED/41289566)
- Manage bone metastases proactively with antiresorptive agents like denosumab and palliative radiotherapy to reduce skeletal-related events and improve quality of life.[3](https://pubmed.ncbi.nlm.nih.gov/41707577/)
- Radiotherapy planning matters: Techniques like deep inspiration breath-hold can substantially reduce cardiac and esophageal doses in stage III NSCLC.[4](https://pubmed.ncbi.nlm.nih.gov/41687662/)
- Stay current with evolving biomarkers and therapies: Novel targets such as PKMYT1, NIX/BNIP3L, and non-coding RNAs illustrate how rapidly lung cancer biology and treatment are advancing.[1](https://pubmed.ncbi.nlm.nih.gov/41815149/), [2](https://pubmed.ncbi.nlm.nih.gov/41744611/), [6](https://europepmc.org/article/MED/39483961), [8](https://europepmc.org/article/MED/41735617)